Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Lung cancer is the leading cause of cancer related death, and is divided into two major
histological subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …

Resistance mechanisms to osimertinib and emerging therapeuti... : Current Opinion in
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …

The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

Currently, the mechanisms of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) resistance have been a focus of clinical research. Despite that most of the …